PT861073E - Preparacoes de hormona da tiroide estabilizadas e metodos para prepara-las - Google Patents

Preparacoes de hormona da tiroide estabilizadas e metodos para prepara-las

Info

Publication number
PT861073E
PT861073E PT96938414T PT96938414T PT861073E PT 861073 E PT861073 E PT 861073E PT 96938414 T PT96938414 T PT 96938414T PT 96938414 T PT96938414 T PT 96938414T PT 861073 E PT861073 E PT 861073E
Authority
PT
Portugal
Prior art keywords
preparations
disclosed
thyroid hormone
preparing
methods
Prior art date
Application number
PT96938414T
Other languages
English (en)
Portuguese (pt)
Inventor
K Mitra Amit
Raghunath Srinivas
Charles L Thomas Iii
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of PT861073E publication Critical patent/PT861073E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT96938414T 1995-11-14 1996-11-14 Preparacoes de hormona da tiroide estabilizadas e metodos para prepara-las PT861073E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US673895P 1995-11-14 1995-11-14
US1731496P 1996-05-13 1996-05-13

Publications (1)

Publication Number Publication Date
PT861073E true PT861073E (pt) 2004-10-29

Family

ID=26675995

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96938414T PT861073E (pt) 1995-11-14 1996-11-14 Preparacoes de hormona da tiroide estabilizadas e metodos para prepara-las

Country Status (12)

Country Link
US (2) US5955105A (enExample)
EP (1) EP0861073B1 (enExample)
JP (1) JP2000500155A (enExample)
AT (1) ATE271863T1 (enExample)
AU (1) AU712217B2 (enExample)
BR (1) BR9611306A (enExample)
CA (1) CA2235707A1 (enExample)
DE (1) DE69633018T2 (enExample)
ES (1) ES2224184T3 (enExample)
MX (1) MXPA98003802A (enExample)
PT (1) PT861073E (enExample)
WO (1) WO1997017951A1 (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
DE19830246A1 (de) * 1998-07-07 2000-01-13 Merck Patent Gmbh Pharmazeutische Zubereitung
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU3699000A (en) * 1999-03-10 2000-09-28 Lotus Biochemical Corporation Use of protein conformation for the protection and release of chemical compounds
AU783656B2 (en) * 1999-09-02 2005-11-24 Nostrum Pharmaceuticals, Inc. Controlled release oral dosage suitable for oral administration
US6627660B1 (en) 1999-11-16 2003-09-30 New River Pharmaceuticals Inc. Stabilized thyroxine compounds
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
JP4902928B2 (ja) * 2000-05-24 2012-03-21 大塚製薬株式会社 製剤の安定化方法
EP1157682A1 (en) * 2000-05-25 2001-11-28 Cilag AG Blister package for topiramate tablets
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6855333B1 (en) * 2000-10-03 2005-02-15 Mutual Pharmaceutical Co., Inc. Stabilization of solid thyroid drug formulations
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
ITMI20011401A1 (it) * 2001-07-02 2003-01-02 Altergon Sa Formulazioni farmaceutiche per ormoni tiroidei
AU2002332507A1 (en) * 2001-08-10 2003-02-24 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030194436A1 (en) * 2001-08-10 2003-10-16 Franz Andrew G. Immediate release pharmaceutical compositions
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030199585A1 (en) * 2001-08-10 2003-10-23 Franz G Andrew Levothyroxine compositions and methods
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
WO2003028624A2 (en) * 2001-08-14 2003-04-10 King Pharmaceuticals, Inc Levothyroxine compositions and methods
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US7101569B2 (en) * 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030194437A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Cmax properties
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
EP1429756B1 (en) 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030175337A1 (en) * 2001-10-29 2003-09-18 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
CA2472690A1 (en) * 2002-01-07 2003-07-17 Abbott Gmbh & Co. Kg Crystallization of amino acids using ultrasonic agitation
AU2003241537A1 (en) * 2002-05-23 2003-12-12 Andrx Corporation Biguanide formulations
AU2003268078A1 (en) * 2002-08-10 2004-02-25 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
EP1565171A4 (en) * 2002-11-05 2010-06-30 Shire Llc PROGRESSIVE ABSORPTION OF MIXED FORMULATIONS OF THYROID HORMONES
CA2504916A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022394A1 (it) * 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
DE602004018617D1 (de) * 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081004A1 (en) * 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US8293272B2 (en) * 2003-05-02 2012-10-23 Globopharm Pharmazeutische Produktions-Und Handelsgesellschaft M.B.H. Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
EP1622587B1 (de) * 2003-05-02 2010-04-28 Globopharm Pharmazeutische Produktions- und Handelsgesellschaft m.b.H. Feste pharmazeutische zubereitung enthaltend levothyroxin- und/oder liothyroninsalze
GB0316206D0 (en) * 2003-07-10 2003-08-13 Glaxo Group Ltd Pharmaceutical formulation
US20060008512A1 (en) * 2004-07-07 2006-01-12 Hooge Danny M Composition and methods for improved animal performance
ATE519480T1 (de) * 2006-01-06 2011-08-15 Intervet Int Bv Konzentrierte flüssige schilddrüsenhormonzusammensetzung
US7858663B1 (en) 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
GB2457710A (en) * 2008-02-25 2009-08-26 Andrew Nicolaou Thyroxine and its use in weight loss and obesity treatment
IT1395454B1 (it) * 2009-03-24 2012-09-21 Altergon Sa Composizioni e forme farmaceutiche per somministrazione orale di ormoni tiroidei in grado di contrastare l'azione di agenti sequestranti nel tratto gastrointestinale
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
EP2461804A4 (en) * 2009-08-04 2013-10-02 Haren Treasurer IMPROVED USE WITH THYROID HORMONE
JP5990176B2 (ja) 2010-10-12 2016-09-07 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
KR101865883B1 (ko) * 2011-04-08 2018-06-08 브라코 이미징 에스.피.에이. 3,5-디요오도-ｏ-[3-요오도페닐]-ｌ-티로신의 황산화 유도체의 제조 방법
WO2013033194A1 (en) 2011-08-30 2013-03-07 Fresenius Kabi Usa, Llc Levothyroxine formulations
US8779000B1 (en) * 2013-07-20 2014-07-15 Nilesh Parikh Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production
EP2932963A1 (en) * 2014-04-16 2015-10-21 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable pharmaceutical dosage forms comprising Levothyroxine sodium
US11154498B2 (en) 2015-07-22 2021-10-26 Leiutis Pharmaceuticals Pvt. Ltd. Stabilized liquid formulation of levothyroxine
US11364196B2 (en) 2015-11-04 2022-06-21 Leiutis Pharmaceuticals Pvt. Ltd. Levothyroxine formulations for oral use
NL2017110B1 (en) * 2016-07-05 2018-01-12 Emp Levo Gmbh Methods for the preparation of a levothyroxine solution
US10231931B1 (en) 2018-03-23 2019-03-19 Genus Lifesciences Inc. Thyroid hormone oral dosage forms and methods of using the same
WO2022075436A1 (en) * 2020-10-09 2022-04-14 Aska Pharmaceutical Co., Ltd. A method of producing thyroid hormone-containing formulation
WO2023088976A1 (en) 2021-11-16 2023-05-25 Tap Pharmaceuticals, Ag Orodispersible levothyroxine compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5275820A (en) * 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5225204A (en) * 1991-11-05 1993-07-06 Chen Jivn Ren Stable dosage of levothyroxine sodium and process of production
ES2115638T3 (es) * 1991-12-30 1998-07-01 Akzo Nobel Nv Composicion tiroactiva de liberacion controlada.
DE4318577A1 (de) * 1993-06-04 1994-12-08 Merck Patent Gmbh Schmiermittelfreie, arzneimittelhaltige Tabletten
GB9401879D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
GB9401892D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
HUT75956A (en) * 1995-11-29 1997-05-28 Cyclolab Pharmaceutical composition containing thyroxine

Also Published As

Publication number Publication date
ATE271863T1 (de) 2004-08-15
MXPA98003802A (es) 2005-04-29
ES2224184T3 (es) 2005-03-01
US5955105A (en) 1999-09-21
AU712217B2 (en) 1999-11-04
EP0861073A1 (en) 1998-09-02
DE69633018D1 (de) 2004-09-02
EP0861073B1 (en) 2004-07-28
DE69633018T2 (de) 2004-12-09
JP2000500155A (ja) 2000-01-11
US6056975A (en) 2000-05-02
BR9611306A (pt) 1999-12-28
AU7584996A (en) 1997-06-05
CA2235707A1 (en) 1997-05-22
WO1997017951A1 (en) 1997-05-22

Similar Documents

Publication Publication Date Title
MXPA98003802A (es) Preparaciones de hormona tiroidea estabilizadas ymetodos para fabricar las mismas.
DE68904121D1 (de) Ibuprofen-cyclodextrin-einschlusskomplexe enthaltende pharmazeutische zubereitungen.
CA2033725A1 (en) Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
EP0787497A3 (en) Pharmaceutical preparation containing human growth hormone
AU7038587A (en) Amino acid chelated compositions
BG101781A (bg) Твърд препарат, съдържащ активно вещество
AU678344B2 (en) Lipophilic oligosaccharide antibiotic salt compositions
BR9812835A (pt) Composição de gel para barbear não-aerossol
DE69726457D1 (de) Pharmazeutische zusammensetzungen mit antimikrobieller wirkung
GR3036966T3 (en) Stabilized pseudo-emulsions and their preparation process
AU566228B2 (en) Compressed hydroxybutryic acid polymer retarded release vehicle
KR900014406A (ko) 세펨 화합물 및 이의 제조방법
FR2380782A1 (fr) Fraction 5 de thymosine stabilisee utile comme medicament et procede pour la preparer
TW372193B (en) Novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredient
JPS6416724A (en) Stable and injectable vinca dimer salt solution
NZ331083A (en) Pharmaceutical preparations of cilansetron stabilized against racemization
AU8595791A (en) Galactomannan derivatives for coating or embedding medicinally active substances
AU618896B2 (en) Stable solutions of rebeccamycin analog and preparation thereof
AU629445B2 (en) Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol
FR2794976B1 (fr) Compositions pharmaceutiques a action cicatrisante ou anti-complementaire comprenant un derive de dextrane
GB2258397A (en) Pharmaceutical compositions containing amethocaine
JPS57200361A (en) "indomethacin(r)" pharmaceutical with low irritant action
KR900015732A (ko) 경구용 제제
EP0492747A3 (en) Pharmaceutical preparation for topical application
BR9914125A (pt) Composições farmacêuticas baseadas em alfa-ciclodextrina para administração oral de análogos lh-rh